Searching for modulating effects of SCA2, SCA6 and DRPLA CAG tracts on the Machado-Joseph disease (SCA3) phenotype

Acta Neurologica Scandinavica

Volumn 107, Issue 3, 2003, Pages 211-214

  Jardim, Laura ^a,b   Silveira, I ^c   Pereira, M L ^a,b   Do Ceu Moreira M ^c   Mendonca P ^c   Sequeiros, J ^c   Giugliani, R ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

CAG expansions; Machado Joseph disease; Spinocerebellar ataxias

Indexed keywords

GENE PRODUCT; PROTEIN DRPLA; PROTEIN SCA2; PROTEIN SCA6; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALLELISM; AMBULATORY CARE; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BRAZIL; CEREBELLAR ATAXIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MACHADO JOSEPH DISEASE; NEUROLOGIC EXAMINATION; ONSET AGE; PHENOTYPE;

AGE OF ONSET; CALCIUM CHANNELS; CASE-CONTROL STUDIES; HUMANS; MACHADO-JOSEPH DISEASE; NERVE TISSUE PROTEINS; PROGNOSIS; PROTEINS; SEVERITY OF ILLNESS INDEX; TRINUCLEOTIDE REPEATS;

EID: 0344838660     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00046.x     Document Type: Article

References (29)

1. NAKANO KK, DAWSON DM. SPENCE A. Machado disease. A hereditary ataxiain Portuguese emigrants to Massachussetts. Neurology 1972;22:49.
2. WOODS BT, SCHAUMBURG HH. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci 1972;17:149-66.
3. ROSENBERG RN, NYHAN WL, BAY C, SHORE P. Autosomal dominant striatonigral degeneration. Neurology 1976;26:703-14.
4. COUTINHO P, ANDRADE C. Autosomal Dominant system degeneration in Portuguese families of the Azores Islands. Neurology 1978;28:703-9.
5. KAWAGUCHI Y, OKAMOTO T, TANIWAKI M et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nature Genet 1994;8:221-8.
6. MACIEL P, GASPAR C, DESTEFANO AL et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995;57:54-61.
7. MARUYAMA H, NAKAMURA S, MATSUYAMA Z et al. Molecular features of the CAG repeats and clinical manifestatin of Machado-Joseph disease. Hum Mol Genet 1995;4:807-12.
8. SEQUEIROS J, COUTINHO P. Epidemiology and clinical aspects of Machado-Joseph disease. In: HARDING A. DEUFEL T, CHAMBERLAIN S, eds. Hereditary ataxias. Advance neurology, Vol. 61. New York: Raven Press, 1993;139-53.
9. JARDIM LB, PEREIRA ML, SILVEIRA I, FERRO A, SEQUEIROS J, GIUGLIANI R. Machado-Joseph disease in South Brazil: clinical and molecular characterization of kindreds. Acta Neurol Scand 2001;104:224-31.
10. JUNCK L, FINK JK. Machado-Joseph disease and SCA3: the genotype meets the phenotypes. Neurology 1996;46:4-8.
11. JARDIM LB, PEREIRA ML, SILVEIRA I, FERRO A, SEQUEIROS J, GIUGLIANI R. Neurological findings in Machado-Joseph disease: their relation with disease duration, clinical types and CAG repeat lengths. Arch Neurol 2001;58:899-904.
12. TAKIYAMA Y, IGARASHI S, ROGAEVA EA et al. Evidence for intergenerational instability in the MJD1 gene and for conserved haplotypes at flanking markers amongst Japanese and Caucasian subjects with Machado-Joseph disease. Hum Molec Genet 1995;4:1137-46.
13. ROSENBERG RN. Autosomal dominant cerebellar phenotypes: the genotype has settled the issue. Neurology 1995;45:1-5.
14. HACKAM AS, WELLINGTON CL, E HAYDEN MR. The fatal attraction of polyglutamine-containing proteins. Clin Genet 1998;54 (Suppl. 1):23-32.
15. KAKIZUKA A. Protein precipitation: a common etiology in neurodegenerative disorders? Trends Genet 1998;14:396-402.
16. HARDY J, GWINN-HARDY K. Genetic classification of primary neurodegenerative disease. Science 1998;282:1075-8.
17. ORR HT, CHUNG M, BANFI S et al. Expansion of an unstable trinucleotide (CAG) repeat in spinocerebellar ataxia type I. Nature Genet 1993;4:221-6.
18. KOIDE R, IKEUCHI T, ONODERA O et al. Unstable expression of CAG repeat in hereditary dentatorubralpallidoluysian atrophy (DRPLA). Nature Genet 1994;6:9-13.
19. PULST S-M, NECHIPORUK A, NECHIPORUK T et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996;14:269-76.
20. DAVID G, ABBAS N, STEVANIN G et al. Cloning the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997;17:65-70.
21. IA-Voltage-dependent calcium channel. Nature Genet 1997;15:62-8.
22. HOLMES SE, O'HEARN EE, MCINNIS MG et al. Expansion of a novel CAG trinucleotide repeat in the 5′ region of PPP2R2B is associated with. SCA12 [Letter] Nat Genet 1999;23:391-2.
23. PERUTZ MF. Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. Mol Med 1995;1:718-21.
24. HAYES S, TURECKI G, BRISEBOIS K et al. CAG repeat length in RA11 is associated with age at onset variability in spinocerebellar ataxia type 2 (SCA2). Human Mol Genet 2000;9:1753-8.
25. HOLBERT S, DENGHIEN I, KIECHLE T et al. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin. Neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proc Natl Acad Sci USA;98:1811-6 (13 February 2001).
26. SAMBROOK J, FRITSCH EF, MANIATIS T. Molecular cloning: a laboratory manual. New York: Cold Spring Harbor Laboratory Press, 1989.
27. SILVEIRA I, COUTINHO P, MACIEL P et al. Molecular genetic studies in spinocerebellar ataxias: analysis of SCA1, DRPLA and MJD mutations in patients from 48 Portuguese ataxia families. Am J Med Genet (Neuropsychiat Genet) 1998;81:134-8.
28. GESCHWIND DH, PERLMAN S, FIGUEROA CP, TREIMAN LJ, PULST S. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 1997;60:842-50.
29. CHATAWAY J, SAWCER S, CORADDU F et al. Evidence that allelic variants of the spinocerebellar ataxia type 2 gene influence susceptibility to multiple sclerosis. Neurogenetics April 1999;2:91-6.